Literature DB >> 20391508

Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort.

Kiem Oen1, Ciarán M Duffy, Shirley M L Tse, Suzanne Ramsey, Janet Ellsworth, Gaëlle Chédeville, Anne-Laure Chetaille, Claire Saint-Cyr, David A Cabral, Lynn R Spiegel, Rayfel Schneider, Bianca Lang, Adam M Huber, Paul Dancey, Earl Silverman, Alan M Rosenberg, Bonnie Cameron, Nicole Johnson, Jean Dorval, Rosie Scuccimarri, Sarah Campillo, Ross E Petty, Karen N Watanabe Duffy, Gilles Boire, Elie Haddad, Kristin Houghton, Ronald Laxer, Stuart E Turvey, Paivi Miettunen, Katherine Gross, Jaime Guzman, Susanne Benseler, Brian M Feldman, Victor Espinosa, Rae S M Yeung, Lori Tucker.   

Abstract

OBJECTIVE: To determine early outcomes and early improvements in a prospective inception cohort of children with juvenile idiopathic arthritis (JIA) treated with current standard therapies.
METHODS: Patients selected were enrolled in an inception cohort of JIA, the Research in Arthritis in Canadian Children Emphasizing Outcomes Study. The juvenile rheumatoid arthritis core criteria set measures were completed at enrollment and 6 months later. Frequencies of normal values for each of the core set measures and the American College of Rheumatology (ACR) Pediatric 30, 50, and 70 (Pedi 70) criteria response rates achieved at 6 months after enrollment were calculated for each JIA-onset subtype group.
RESULTS: Among 354 patients in the study, the median interval between diagnosis and enrollment was 0.7 months. At 6 months after enrollment, median values of active joint counts were highest in patients with rheumatoid factor (RF)-positive polyarthritis (4) and RF-negative polyarthritis (2), but were 0 or 1 for other subtypes. Fifty percent or more of patients with oligoarthritis, systemic arthritis, enthesitis-related arthritis, and undifferentiated arthritis had no active joints, and the ACR Pedi 70 criteria response rate was 48% or more in those with oligoarthritis, RF-negative polyarthritis, and systemic arthritis.
CONCLUSION: With current management strategies in clinical practice, improvement in disease activity was noted in considerable proportions of patients in all of the JIA subtype groups, but low levels of disease activity persisted in many. We expect that these early outcomes will prove to be significant predictors of long-term outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20391508     DOI: 10.1002/acr.20044

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  19 in total

Review 1.  [New therapy approaches, better outcomes? : Results from inception cohorts for patients with juvenile idiopathic arthritis].

Authors:  C Sengler
Journal:  Z Rheumatol       Date:  2019-09       Impact factor: 1.372

Review 2.  Imaging in Juvenile Spondyloarthritis.

Authors:  Pamela F Weiss; Nancy A Chauvin; Johannes Roth
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

3.  Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.

Authors:  Katherine J Donnithorne; Randy Q Cron; Timothy Beukelman
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

Review 4.  New advances in juvenile spondyloarthritis.

Authors:  Shirley M L Tse; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2012-04-10       Impact factor: 20.543

Review 5.  Assessment and management of pain in juvenile idiopathic arthritis.

Authors:  Jennifer N Stinson; Nadia J C Luca; Lindsay A Jibb
Journal:  Pain Res Manag       Date:  2012 Nov-Dec       Impact factor: 3.037

6.  Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study.

Authors:  Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam
Journal:  Health Technol Assess       Date:  2020-07       Impact factor: 4.014

Review 7.  Juvenile spondyloarthropathies.

Authors:  R Hal Scofield; Andrea L Sestak
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

Review 8.  Enthesitis-related arthritis.

Authors:  Amita Aggarwal; Durga Prasanna Misra
Journal:  Clin Rheumatol       Date:  2015-08-02       Impact factor: 2.980

9.  Discordant inflammatory changes in the apophyseal and sacroiliac joints: serial observations in enthesitis-related arthritis.

Authors:  Timothy J P Bray; Thomas Amies; Kanimozhi Vendhan; Paul Humphries; Debajit Sen; Yiannis Ioannou; Margaret A Hall-Craggs
Journal:  Br J Radiol       Date:  2016-07-04       Impact factor: 3.039

10.  Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.

Authors:  Timothy Beukelman; Sarah Ringold; Trevor E Davis; Esi Morgan DeWitt; Christina F Pelajo; Pamela F Weiss; Yukiko Kimura
Journal:  J Rheumatol       Date:  2012-08-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.